In a document published in the Federal Register , the Drug Enforcement Administration (DEA) announced it will hold a hearing on August 22, 2022 , on its controversial proposal to place five psychedelic compounds in Schedule I.
The first plan to schedule the five tryptamines - 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT - was published in January. Both the research and advocacy communities disavowed it during a public comment period and requested a hearing, which was ultimately granted .
This initial rulemaking filing would have been made considering research and recommendations from the U.S. Department of Health and Human Services (HHS) stating that “these substances are being abused for their hallucinogenic properties,” after identified cases of hospitalizations related to the use of two of the tryptamines.
Yet, investigations were only able to cite one death where one of the compounds, ...
Full story available on Benzinga.com